Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Terminated 4Suspended 2Recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 1CNS 1

Conditions

Multiple Myeloma 1Glioma 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Glucose × Clear all
NCT02253316 2025-11-10

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Washington University School of Medicine

Phase 2 Active not recruiting
236 enrolled 13 charts
Plasma cell

Multiple Myeloma

NCT06594315 2025-09-18

Assessing Brain Metabolism Using MRS With Deuterated Glucose

University of California, San Francisco

Active not recruiting
80 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡